NDRA Stock Price, ENDRA Life Sciences Inc Quote, Chart

Market Summary

USD0.31+0.03

Market Closed

10.71%

NDRA Stock Price

View Fullscreen

NDRA RSI Chart

NDRA Valuation

Market Cap

3.4M

Price/Earnings (Trailing)

-0.35

Price/Sales (Trailing)

518.36

EV/EBITDA

-0.23

Price/Free Cashflow

-0.37

NDRA Price/Sales (Trailing)

NDRA Profitability

Operating Margin

100.00%

EBT Margin

-160239.78%

Return on Equity

-267.52%

Return on Assets

-195.49%

Free Cashflow Yield

-269.51%

NDRA Fundamentals

NDRA Revenue

Revenue (TTM)

6.2K

NDRA Earnings

Earnings (TTM)

-9.9M

Earnings Growth (Yr)

5.68%

Earnings Growth (Qtr)

-90.18%

Breaking Down NDRA Revenue

Last 7 days

3.3%

Last 30 days

34.8%

Last 90 days

-73.0%

Trailing 12 Months

-78.3%

How does NDRA drawdown profile look like?

NDRA Financial Health

Current Ratio

1.04

NDRA Investor Care

Shares Dilution (1Y)

47.50%

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2018	265.3K	178.9K	92.5K	6.2K
2017	0	460.9K	406.3K	351.6K
2016	0	0	0	515.6K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of ENDRA Life Sciences Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
May 18, 2023	thornton michael milos	bought	24,750	1.65	15,000	chief technology officer
May 02, 2023	digiandomenico anthony	bought	99,999	1.2	83,333	-
Dec 09, 2022	thornton michael milos	bought	5,100	3.4	1,500	chief technology officer
Nov 23, 2022	tokman alexander y	bought	1,700	0.17	10,000	-
Aug 22, 2022	tokman alexander y	bought	5,200	0.26	20,000	-
Aug 22, 2022	thornton michael milos	bought	5,400	0.27	20,000	chief technology officer
May 26, 2022	thornton michael milos	bought	5,250	0.21	25,000	chief technology officer
May 18, 2022	thornton michael milos	bought	5,500	0.22	25,000	chief technology officer
May 17, 2022	michelon francois roger	bought	969	0.19	5,100	chief executive officer
May 16, 2022	tokman alexander y	bought	19,630	0.1963	100,000	-

Which funds bought or sold NDRA recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	JANE STREET GROUP, LLC	new	-	20,947	20,947	-%
May 15, 2024	NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO	unchanged	-	-506	191	-%
May 15, 2024	TWO SIGMA SECURITIES, LLC	new	-	27,790	27,790	-%
May 15, 2024	Tower Research Capital LLC (TRC)	added	190	-1,304	5,020	-%
May 15, 2024	MORGAN STANLEY	unchanged	-	-511	193	-%
May 14, 2024	NewEdge Advisors, LLC	reduced	-1.02	-48,303	17,958	-%
May 13, 2024	GEODE CAPITAL MANAGEMENT, LLC	added	3.95	-79,208	31,477	-%
May 13, 2024	UBS Group AG	new	-	81.00	81.00	-%
May 13, 2024	XTX Topco Ltd	new	-	6,240	6,240	-%
May 13, 2024	FMR LLC	added	1,500	7.00	9.00	-%

Are Funds Buying or Selling NDRA?

Are funds buying NDRA calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own NDRA

No. of Funds

Unveiling ENDRA Life Sciences Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Mar 10, 2023	bryan michael sr	6.1%	0	SC 13G

Recent SEC filings of ENDRA Life Sciences Inc

View All Filings

Date Filed	Form Type	Document
May 14, 2024	10-Q	Quarterly Report
May 14, 2024	8-K	Current Report
May 10, 2024	8-K	Current Report
May 10, 2024	S-1/A	Initial Public Offering
May 03, 2024	8-K	Current Report
Apr 19, 2024	S-1	Initial Public Offering
Apr 03, 2024	424B5	Prospectus Filed
Apr 03, 2024	EFFECT	EFFECT
Apr 03, 2024	424B5	Prospectus Filed
Apr 01, 2024	CORRESP	CORRESP

Peers (Alternatives to ENDRA Life Sciences Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
DHR	196.9B	23.7B	11.04%	17.40%	44.73	8.29	-8.94%	-35.91%
A	45.2B	6.7B	14.64%	19.44%	36.57	6.71	-2.81%	-6.58%
IDXX	44.9B	3.7B	13.71%	10.52%	51.83	12.06	8.57%	23.94%
DGX	16.0B	9.3B	13.66%	10.24%	18.95	1.73	-3.29%	6.68%
NTRA	13.1B	1.2B	17.80%	114.36%	-35.76	10.81	39.26%	33.08%
MEDP	12.2B	2.0B	2.71%	87.82%	38.94	6.2	25.57%	21.62%
CRL	11.4B	4.1B	-3.66%	11.24%	26.02	2.78	0.49%	-11.59%
EXAS	9.3B	2.5B	-20.33%	-38.03%	-38.69	3.67	15.21%	53.51%
MID-CAP
GH	3.1B	603.7M	54.73%	-14.09%	-6.73	5.14	25.21%	30.68%
NEOG	2.9B	929.2M	11.70%	-18.80%	1.9K	3.16	28.93%	111.61%
SMALL-CAP
CDNA	808.3M	275.1M	87.44%	103.94%	-4.41	2.94	-13.93%	-126.97%
ACRS	84.8M	31.1M	-3.25%	-85.34%	-1.1	2.73	0.95%	19.75%
AWH	33.0M	9.2M	-24.07%	-37.65%	-2.24	3.6	11.85%	45.80%
APDN	2.5M	5.5M	-62.31%	120.18%	-0.2	0.45	-68.52%	-141.15%
BIOC	183.8K	25.9M	-50.00%	-94.83%	-0.01	0.01	-57.78%	-93.11%

ENDRA Life Sciences Inc News

Latest updates

ENDRA Life Sciences Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)								(In Thousands)
Description	(%) Q/Q	2018Q4	2018Q3	2018Q2	2018Q1	2017Q4	2017Q3	2017Q2	2016Q4
Revenue	-100.0%	-	2.00	3.00	5.00	7.00	287	58.00	-
Gross Profit	-	-	-	-	6.00	4.00	169	6.00	-
Operating Expenses	-15.0%	2,003	2,356	1,823	-	-	-	-	-
S&GA Expenses	-41.9%	42.00	72.00	41.00	-	-	-	-	-
R&D Expenses	-9.6%	1,051	1,163	840	-	-	-	-	-
Interest Expenses	-	40.00	-	-	-	-	-	-	-
Income Taxes	-	-	-	-	-	-	-	-	-
Earnings Before Taxes	14.2%	-2,365	-2,758	-1,846	-	-	-	-	-
Net Income	14.2%	-2,365	-2,758	-1,846	-	-	-	-	-

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-25.1%	5,061	6,754	7,603	9,245	6,655	9,274	12,343	15,309	10,937	12,875	15,314	17,243	18,899	8,765	5,361	2,863	4,399	7,176	3,615	3,191	4,637
Current Assets	-58.1%	1,271	3,033	6,398	8,084	5,519	5,379	11,565	14,488	10,119	12,094	14,470	16,343	18,351	8,208	4,780	2,275	3,773	6,535	2,976	2,952	4,378
Cash Equivalents	-60.0%	1,135	2,834	3,335	4,819	2,355	4,889	8,016	11,278	7,127	9,462	11,793	14,043	16,843	7,227	3,793	749	3,103	6,174	2,275	2,268	3,925
Inventory	3.4%	2,712	2,623	2,758	2,758	2,735	2,645	2,634	2,375	1,930	1,285	1,500	1,325	727	590	323	341	175	113	128	74.00	74.00
Net PPE	-0.3%	111	112	161	193	228	236	231	240	201	131	162	192	226	212	226	215	237	236	219	239	259
Liabilities	24.4%	1,363	1,095	2,407	2,314	2,156	2,070	2,139	1,975	1,868	2,090	2,158	2,253	1,047	1,596	2,026	1,886	1,877	2,416	2,213	1,366	835
Current Liabilities	34.7%	1,217	903	2,169	2,033	1,832	1,704	1,705	1,502	1,358	1,544	1,577	1,638	766	987	1,399	1,240	1,551	2,073	1,854	-	-
Short Term Borrowings	-100.0%	-	28.00	28.00	28.00	-	28.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Long Term Debt	-	-	-	-	281	324	-	434	473	510	547	-	-	-	609	-	-	-	-	-	-	-
Shareholder's Equity	-34.6%	3,698	5,659	5,196	6,931	4,499	7,205	10,203	13,334	9,069	10,784	13,156	14,990	17,852	7,169	3,335	977	2,522	4,761	1,403	1,824	3,802
Retained Earnings	-3.0%	-94,705	-91,930	-90,470	-87,369	-84,812	-81,869	-78,580	-75,140	-71,549	-68,690	-65,586	-62,927	-59,728	-57,338	-55,087	-51,434	-48,540	-45,217	-36,188	-32,774	-30,440
Additional Paid-In Capital	0.8%	98,403	97,583	95,664	94,297	89,308	89,068	88,769	88,462	80,604	79,461	78,695	77,839	77,461	64,494	58,282	52,228	50,982	49,934	37,590	34,598	34,241
Shares Outstanding	6.2%	11,036	10,390	8,412	7,482	3,169	3,169	3,159	3,159	2,153	2,128	2,108	2,093	1,889	-	-	-	-	-	-	-	-
Float	-	-	-	-	10,257	15,628	-	-	-	-	-	-	90,010	-	-	-	23,166	-	-	-	12,171	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	1.4%	-2,144	-2,174	-2,598	-2,268	-2,506	-3,088	-3,246	-3,334	-3,098	-2,652	-2,746	-2,799	-2,923	-2,073	-2,133	-3,451	-3,088	-1,907	-2,482	-1,657	-2,540
Share Based Compensation	26.7%	317	251	253	256	237	291	909	-288	289	412	328	383	322	-	-	-	-	-	-	-	-
Cashflow From Investing	-1144.1%	-23.80	2.00	-	-	-27.00	-38.56	-14.86	-59.80	-89.35	-	-	-	-45.00	-64.85	12.00	-	-22.35	-38.36	-	1*	-5.24
Cashflow From Financing	-72.0%	469	1,672	1,114	4,733	-	-	-	7,545	854	321	497	-	12,584	5,572	5,166	1,097	39.00	5,845	2,491	-	-
Dividend Payments	-	-	-	-	-	-	-	-	-	-	-	-	5.00	22.00	-	-90.27	172	-34.07	-	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

NDRA Income Statement

2024-03-31

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating Expenses
Research and development	$ 1,041,526	$ 1,391,314
Sales and marketing	238,660	181,616
General and administrative	1,500,355	1,366,398
Total operating expenses	2,780,541	2,939,328
Operating loss	(2,780,541)	(2,939,328)
Other Expenses
Other income (expense)	4,841	(3,418)
Total other expenses	4,841	3,418
Loss from operations before income taxes	(2,775,700)	(2,942,746)
Provision for income taxes	0	0
Net Loss	$ (2,775,700)	$ (2,942,746)
Net loss per share - basic and diluted	$ (0.26)	$ (0.93)
Weighted average common shares - basic and diluted	10,804,625	3,169,103

NDRA Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Cash	$ 1,134,701	$ 2,833,907
Prepaid expenses	135,821	198,905
Total Current Assets	1,270,522	3,032,812
Non-Current Assets
Inventory	2,711,923	2,622,865
Fixed assets, net	111,470	111,782
Right of use assets	313,715	354,091
Prepaid expenses, long term	647,085	626,610
Other assets	5,986	5,986
Total Assets	5,060,701	6,754,146
Current Liabilities
Accounts payable and accrued liabilities	1,038,465	700,754
Lease liabilities, current portion	178,239	173,857
Loans	0	28,484
Total Current Liabilities	1,216,704	903,095
Long Term Debt
Loans, long term	0	0
Lease liabilities	145,825	192,062
Total Long Term Debt	145,825	192,062
Total Liabilities	1,362,529	1,095,157
Stockholders' Equity
Common stock, $0.0001 par value; 80,000,000 shares authorized; 10,914,447 and 10,390,150 shares issued and outstanding, respectively	1,092	1,039
Additional paid in capital	98,402,631	97,582,868
Stock payable	301	5,233
Accumulated deficit	(94,705,852)	(91,930,152)
Total Stockholders' Equity	3,698,172	5,658,989
Total Liabilities and Stockholders' Equity	5,060,701	6,754,146
Series A Convertible Preferred Stock
Stockholders' Equity
Preferred stock value	0	1
Series B Convertible Preferred Stock
Stockholders' Equity
Preferred stock value	0	0
Series C Convertible Preferred Stock
Stockholders' Equity
Preferred stock value	$ 0	$ 0

About ENDRA Life Sciences Inc

ENDRA Life Sciences Inc. develops technology for improving the capabilities of clinical diagnostic ultrasound. The company develops thermo-acoustic enhanced ultrasound technology that transmits sound waves, which bounce off tissues, organs, and blood in the body for use in the treatment of nonalcoholic fatty liver disease, as well as in tissue composition, temperature monitoring, vascular imaging, and tissue perfusion. It also offers diagnostic imaging technologies, such as computed tomography, magnetic resonance imaging, and ultrasound that allow physicians to look inside a person's body to guide treatment or gather information about medical conditions, such as broken bones, cancers, signs of heart disease, or internal bleeding. The company has a collaborative research agreement with General Electric Company. ENDRA Life Sciences Inc. was incorporated in 2007 and is based in Ann Arbor, Michigan.

CEO	Mr. Francois Michelon
WEBSITE	endrainc.com
INDUSTRY	Diagnostics & Research
EMPLOYEES	21

ENDRA Life Sciences Inc Frequently Asked Questions

What is the ticker symbol for ENDRA Life Sciences Inc? What does NDRA stand for in stocks?

NDRA is the stock ticker symbol of ENDRA Life Sciences Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of ENDRA Life Sciences Inc (NDRA)?

As of Fri May 17 2024, market cap of ENDRA Life Sciences Inc is 3.42 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of NDRA stock?

You can check NDRA's fair value in chart for subscribers.

What is the fair value of NDRA stock?

You can check NDRA's fair value in chart for subscribers. The fair value of ENDRA Life Sciences Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of ENDRA Life Sciences Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for NDRA so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is ENDRA Life Sciences Inc a good stock to buy?

The fair value guage provides a quick view whether NDRA is over valued or under valued. Whether ENDRA Life Sciences Inc is cheap or expensive depends on the assumptions which impact ENDRA Life Sciences Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for NDRA.

What is ENDRA Life Sciences Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, NDRA's PE ratio (Price to Earnings) is -0.35 and Price to Sales (PS) ratio is 518.36. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. NDRA PE ratio will change depending on the future growth rate expectations of investors.